Alnylam Pharmaceuticals, Inc.

Hello, everyone. Thank you for joining us, and welcome to the Alnylam Pharmaceuticals Q3 Earnings Conference Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to the company. Please go ahead.

Good morning. I'm Josh Brodsky. Vice President of Investor Relations at El Nilem. With me today are Yvonne Greenstreet, Chief Executive Officer, Tolga Tanguler, Chief Commercialization Officer, Pushkal Garg, Chief Research and Development Officer, and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.elnilem.com slash events. I'd like to remind you that this call will contain remarks concerning Al-Naylam's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important risks and uncertainties, including those discussed under the heading Risk Factors in our most recent periodic report available on our website and on file with the SEC. We disclaim any obligation to update such statements. With that, I'll now turn the call over to Yvonne. Yvonne?

Thanks, Josh, and thank you, everyone, for joining the call today. I'm going to begin by putting the call to into context and discussing why our commercial portfolio and its pipeline give us confidence in our line-up's growth. Tolga will then review our commercial performance and the work underway to expand Ambutra adoption and support patient access. Pushkal will walk through our decision to further expand Triton CM enrolments and importance progress across our pipeline. And finally, Jeff will review our Q3 financial results and our outlook for the fourth quarter and full year before we go to Q&A. I want to start by why we remain confident in the opportunity ahead of our nylam. Amvutra has demonstrated significant benefits for patients with ATTR cardiomyopathy. including reductions in mortality and cardiovascular events with quarterly dosing. We believe that this profile and Amvuta's unique mechanism of action position it to become a foundational treatment in a market where many patients remain untreated and many physicians are still gaining experience with the medicines. Now moving on to the quarter. Our third quarter product revenues grew 52% year-over-year to approximately $1.3 billion. led by continued Amputra uptake, establishing a strong foundation for our TTR franchise. We generated total TTR revenues of $1.15 billion during the third quarter, representing nearly 60% growth year over year. We have deep conviction in the commercial initiatives and investments we authorized earlier this year and have now fully implemented. Given the magnitude of the opportunity in front of us, We believe these are the right actions to broaden Amvutra's prescriber base, deepen physician engagement, and over time, drive adoption at scale. That said, we are not yet satisfied with the underlying demand growth we have observed, and this is reflected in the four-year outlook that Jeff will discuss shortly. As Tolga will describe in more detail, our Salesforce expansion is increasing physician engagement. But that engagement takes time to translate into additional patient starts. We have more work to do, and accelerating that translation is a clear priority for us. With what we believe is a best-in-class clinical profile, demonstrated by continued evidence generation from HVSB, Amvutra continues to offer a significant opportunity to expand physician adoption and reach more patients in the growing ATTR market. and at the same time, the performance of our TTR franchise is funding the future drivers of our Nylans growth. We're investing in and advancing the next wave of medicines as we build a more diversified, multi-franchise business. Within the TTR category, Eucrystrand gives us the opportunity to build on Ambuta's success with deeper TTR lowering and twice-yearly dosing. We have a high level of conviction in a positive trite on CM outcome and today, We announced further expansion of enrollment in the study to approximately 2,250 patients. This expansion optimizes Nucleus Rans chances for success and strengthens our long-term TTR position. Pushkal will go into more detail, but importantly, this expansion does not change our expected ATTR Mario Marti launch timing of 2030, subject to positive study results and regulatory approval. Beyond TTR, The early Rezodoran results we recently reported in Huntington's disease are particularly encouraging. The target engagements and safety findings to date support our preparations to initiate a pivotal study in 2027 pending regulatory alignment. Longer term, our Alnylam 2030 vision continues to guide our priorities and investments for the next half of the decade. Alnylam 2030 represents our aspiration to become the leading science-driven, Fully integrated global biopharmaceutical company and to maximize the full potential of RNAi therapeutics for patients. It also means driving commercial execution with laser-like focus and urgency while continuing to invest in the science that can sustain our Nylums growth over time. We have a substantial opportunity in front of us and our responsibility is to turn it into results for patients and shareholders. With that, Let me now turn the call over to Tolga, who will take you through our commercial progress, including our efforts to expand the prescriber base and reach more patients. Tolga?